921 related articles for article (PubMed ID: 8097319)
1. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff G; Jaffee E; Lazenby A; Golumbek P; Levitsky H; Brose K; Jackson V; Hamada H; Pardoll D; Mulligan RC
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3539-43. PubMed ID: 8097319
[TBL] [Abstract][Full Text] [Related]
2. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
3. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
[TBL] [Abstract][Full Text] [Related]
4. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
5. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.
Nagai E; Ogawa T; Kielian T; Ikubo A; Suzuki T
Cancer Immunol Immunother; 1998 Oct; 47(2):72-80. PubMed ID: 9769115
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
[TBL] [Abstract][Full Text] [Related]
8. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction.
Abe J; Wakimoto H; Yoshida Y; Aoyagi M; Hirakawa K; Hamada H
J Cancer Res Clin Oncol; 1995; 121(9-10):587-92. PubMed ID: 7559742
[TBL] [Abstract][Full Text] [Related]
10. Role of GM-CSF signaling in cell-based tumor immunization.
Zarei S; Schwenter F; Luy P; Aurrand-Lions M; Morel P; Kopf M; Dranoff G; Mach N
Blood; 2009 Jun; 113(26):6658-68. PubMed ID: 19282460
[TBL] [Abstract][Full Text] [Related]
11. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
Salgia R; Lynch T; Skarin A; Lucca J; Lynch C; Jung K; Hodi FS; Jaklitsch M; Mentzer S; Swanson S; Lukanich J; Bueno R; Wain J; Mathisen D; Wright C; Fidias P; Donahue D; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Sugarbaker D; Mihm M; Dranoff G
J Clin Oncol; 2003 Feb; 21(4):624-30. PubMed ID: 12586798
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells.
Yu JS; Burwick JA; Dranoff G; Breakefield XO
Hum Gene Ther; 1997 Jun; 8(9):1065-72. PubMed ID: 9189764
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
Klein C; Bueler H; Mulligan RC
J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863
[TBL] [Abstract][Full Text] [Related]
15. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
Hodi FS; Schmollinger JC; Soiffer RJ; Salgia R; Lynch T; Ritz J; Alyea EP; Yang J; Neuberg D; Mihm M; Dranoff G
Proc Natl Acad Sci U S A; 2002 May; 99(10):6919-24. PubMed ID: 11983866
[TBL] [Abstract][Full Text] [Related]
16. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
17. MCA106 fibrosarcoma cells transduced with granulocyte/macrophage colony-stimulating factor are not superior to the wild-type cells in suppressing the growth of hepatic metastases.
Dong XD; Abdel-Wahab Z; Dematos P; Fong T; Pruitt SK; Seigler HF
J Surg Oncol; 1999 May; 71(1):36-45. PubMed ID: 10362090
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
20. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]